MedTrace Logo

Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery

NCT06904248 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2025-04-01

No results posted yet for this study

Summary

This study aims to evaluate the analgesic efficacy and safety of meloxicam injection in subjects with moderate-to-severe pain following abdominal surgery. The primary efficacy endpoint is the summed pain intensity difference over 24 hours ( SPID24)

Conditions

  • Participants With Acute Moderate to Severe Pain Following Abdominal Surgery

Interventions

DRUG

Meloxicam Injection

Intravenous meloxicam Injection, 30mg every 24 hours, for a total of 2 doses

DRUG

Sodium Chloride Injection

Intravenous Sodium Chloride Injection, 18mg every 24 hours, for a total of 2 doses

Sponsors & Collaborators

  • Yangtze River Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-29
Primary Completion
2024-11-20
Completion
2025-02-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06904248 on ClinicalTrials.gov